Bayer Buys Norways Algeta

Bayer Buys Norway's Algeta

Feb. 26, 2014
Bayer said they are 'convinced of the potential of this drug and the underlying technology to provide patients with innovative treatment options.'

FRANKFURT -- Bayer (IW 1000/88) said Wednesday its 1.9-billion-euro (US$2.6-billion) bid for Norwegian cancer treatment specialist Algeta has been successful and it now holds more than 97% in the firm.

"On expiration of the offer deadline on February 26, Bayer had received acceptances for the voluntary takeover offer for a total of approximately 42.73 million shares, representing approximately 97.28% of Algeta's share capital," the statement said.

The German firm had offered Algeta shareholders 362 kronor per share in cash.

Bayer said it has obtained all regulatory approvals required for completion of the deal.

"The transfer of shares to Bayer and the payment of the offer price will take place in the coming days but no later than March 12," it said. Following that, Bayer would initiate a compulsory acquisition process with the aim of becoming the sole shareholder of Algeta. It would also file for delisting of the Algeta shares from the Oslo Stock Exchange. Bayer said it expected to complete the acquisition in the first quarter of this year.

Bayer and Algeta have been collaborating since 2009 on the development and commercialization of the cancer drug Xofigo.

"The acquisition gives us full control over Xofigo. We are absolutely convinced of the potential of this drug and the underlying technology to provide patients with innovative treatment options," Bayer said.

Copyright Agence France-Presse, 2014

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!